Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 5,931 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Transfusional Iron Overload, Beta-Thalassemia
Interventions: SPD602; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Facial Neuralgia, Pain, Trigeminal Neuralgia
Interventions: Dextromethorphan; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus
Interventions: Generex Oral-lyn™, Regular human insulin; Drug
Lead sponsor: Generex Biotechnology Corp.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 8
States / cities: 2001 Santa Monica Blvd Suite 390W, California • 1150 N. 35th Ave Suite 590, Florida • 7400 North Shadeland Ave, Indiana + 5 more

Conditions: Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
Interventions: Biological: oral polio vaccine, Comparable Placebo, NA-831, Comparable Placebo of drug, Combination of oral polio vaccine and NA-831, Comparable Placebo of Oral Polio Vaccine and Placebo of drug; Biological · Drug · Combination Product
Lead sponsor: Biomed Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 4 more

Conditions: HIV Infections
Interventions: Methadone hydrochloride, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Xerostomia, Sjogren's Syndrome
Interventions: P-552, Placebo; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Ruxolitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 15
States / cities: Highland, California • Montebello, California • Mountain View, California + 12 more

Conditions: Periodontal Diseases
Interventions: Microsurgical approach with Digital Microscope; Procedure
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 18 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: brivanib (active); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 19
States / cities: Duarte, California • Los Angeles, California • Newark, Delaware + 12 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2605541, Human Insulin NPH, Oral Antihyperglycemic Medications (OAM); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 20
States / cities: Tempe, Arizona • Concord, California • Fresno, California + 17 more

Conditions: Microstomia, Scleroderma
Interventions: Hyaluronidase, CO2 laser; Drug · Device
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Omaha, Nebraska

Conditions: Healthy
Interventions: PF-04447943, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Prostate Cancer
Interventions: Kanglaite gelcap; Drug
Lead sponsor: KangLaiTe USA; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: Chicago, Illinois • Evanston, Illinois • Baltimore, Maryland + 2 more

Conditions: Coagulation Disorder
Interventions: TAK-330, SOC 4F-PCC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 13
States / cities: Arkansas City, Arkansas • Sacramento, California • Englewood, Colorado + 10 more

Conditions: Opioid Withdrawal, Opioid Craving, Opioid Use Disorder
Interventions: Epidiolex, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD)
Interventions: Midostaurin; Drug
Lead sponsor: Jason Robert Gotlib; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 3
States / cities: Stanford, California • Boston, Massachusetts • St Louis, Missouri

Conditions: Crohn's Disease
Interventions: STA-5326 mesylate; Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Timeline: Started 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced, Cancer, Metastatic, Tumor, Tumor Recurrence, Tumor Neck, Tumor Metastasis, Oral Cancer, Oropharyngeal Cancer, Oropharynx Cancer, Oropharynx Cancer, Stage III, Oropharynx Cancer, Recurrent, Oropharynx Cancer, Metastatic
Interventions: Pembrolizumab, Radiation therapy, Cisplatin; Drug · Radiation
Lead sponsor: Loren Mell, MD; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 6
States / cities: Tucson, Arizona • La Jolla, California • Tampa, Florida + 3 more

Conditions: Schizophrenia
Interventions: AZD3480; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 66
States / cities: Little Rock, Arkansas • Anaheim, California • Cerritos, California + 63 more

Conditions: Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions: CEA RNA-pulsed DC cancer vaccine; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Myeloid Leukemia
Interventions: AMN107; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 59
States / cities: Mobile, Alabama • Tucson, Arizona • Duarte, California + 48 more

Conditions: Autism
Interventions: Procedure alteration and occupational therapy; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 5 Years to 12 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prostate Cancer
Interventions: Selinexor; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: MT-1186; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Phoenix, Arizona • Rogers, Arkansas • Aurora, Colorado + 9 more

Search by objective public record fields.

Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload

Studies of Dextromethorphan and Topiramate to Treat Oral and Facial Pain

Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)

An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness

Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

Microsurgery and Periodontal Healing

A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

Hyaluronidase Via LADD Scleroderma-induced Microstomia

Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Oral Cannabidiol for Opioid Withdrawal

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia

Biological Therapy in Treating Patients With Metastatic Cancer

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

Program to Improve Dental Care: Children With ASD

SHIP (Selinexor in Hormone Insensitive Prostate Cancer)

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)